{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T23:51:24Z","timestamp":1789775484359,"version":"4.0.1"},"reference-count":67,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T00:00:00Z","timestamp":1676592000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"that there is no funding associated with the work featured in this article"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["OncoImmunology"],"published-print":{"date-parts":[[2023,12,31]]},"DOI":"10.1080\/2162402x.2023.2180237","type":"journal-article","created":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T07:34:37Z","timestamp":1676619277000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":46,"title":["Trial watch: Toll-like receptor ligands in cancer therapy"],"prefix":"10.1080","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3749-2171","authenticated-orcid":false,"given":"Julie","family":"Le Naour","sequence":"first","affiliation":[{"name":"Universit\u00e9 de Paris Cit\u00e9, Sorbonne Universit\u00e9, Inserm U1138, Institut Universitaire de France","place":["Paris, France"]},{"name":"Institut Gustave Roussy","place":["Villejuif, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Kroemer","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Paris Cit\u00e9, Sorbonne Universit\u00e9, Inserm U1138, Institut Universitaire de France","place":["Paris, France"]},{"name":"Institut du Cancer Paris CARPEM","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,2,17]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrg2303"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0502272102"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00461"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2009.08.062"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2010.03.012"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9050439"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2015.58"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1550"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1526250"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1796002"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.1984677"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0796-5"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.705974"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2022-3574"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3708"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1771143"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-8258(22)01540-2"},{"key":"e_1_3_4_19_1","first-page":"5","article-title":"Safety and efficacy of de-escalated neoadjuvant Chemoimmunotherapy of triple negative breast cancer (TNBC) using chemokine-modulating regimen (rintatolimod, IFN-\u03b12b, celecoxib)","volume":"2022","author":"Gandhi SOM","year":"2022","unstructured":"Gandhi SOM, Ford C, Slomba R, Quinn M, O\u2019Connor T, Levine E, Kalinski P. Safety and efficacy of de-escalated neoadjuvant Chemoimmunotherapy of triple negative breast cancer (TNBC) using chemokine-modulating regimen (rintatolimod, IFN-\u03b12b, celecoxib). J ImmunoTherapy Cancer. 2022;2022:5.","journal-title":"J ImmunoTherapy Cancer"},{"key":"e_1_3_4_20_1","first-page":"8","article-title":"Combination of thermally ablative focused ultrasound with gemcitabine controls breast cancer via adaptive immunity","volume":"2020","author":"Sheybani ND","year":"2020","unstructured":"Sheybani ND, Witter AR, Thim EA, Yagita H, Bullock TNJ, Price RJ. Combination of thermally ablative focused ultrasound with gemcitabine controls breast cancer via adaptive immunity. J Immunother Cancer. 2020;2020:8.","journal-title":"J Immunother Cancer"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS9586"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-SITC2021.961"},{"key":"e_1_3_4_23_1","first-page":"1529","article-title":"Reis e Sousa C","volume":"303","author":"Diebold SS","year":"2004","unstructured":"Diebold SS, Kaisho T, Hemmi H, Akira S. Reis e Sousa C. Innate Antiviral Responses by Means of TLR7-mediated Recognition of single-stranded RNA Science. 2004;303:1529\u20131531.","journal-title":"Innate Antiviral Responses by Means of TLR7-mediated Recognition of single-stranded RNA Science"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-SITC2021.472"},{"issue":"15","key":"e_1_3_4_25_1","article-title":"BDB001, an intravenously administered toll-like receptor 7 and 8 (TLR7\/8) agonist, in combination with pembrolizumab in advanced solid tumors: Phase 1 safety and efficacy results","volume":"39","author":"Patel MRTAW","year":"2021","unstructured":"Patel MRTAW, Rasco DW, Johnson ML, Alistar AT, Li L, Chung AH, Andtbacka RHI. BDB001, an intravenously administered toll-like receptor 7 and 8 (TLR7\/8) agonist, in combination with pembrolizumab in advanced solid tumors: Phase 1 safety and efficacy results. J Clin Oncol. 2021;39(15).","journal-title":"J Clin Oncol"},{"key":"e_1_3_4_26_1","article-title":"A first in-human, multicenter, open-label, dose-finding phase 1 study of the immune stimulator antibody conjugate NJH395 in patients with nonbreast HER2+ advanced malignancies","volume":"8","author":"Janku F","year":"2020","unstructured":"Janku F, Doi T, Ajani J, Kuboki Y, Mahling P, Subramanian K, Pelletier M, Askoxylakis V, Siena S. A first in-human, multicenter, open-label, dose-finding phase 1 study of the immune stimulator antibody conjugate NJH395 in patients with nonbreast HER2+ advanced malignancies. J ImmunoTherapy Cancer. 2020;8.","journal-title":"J ImmunoTherapy Cancer"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-21-0722"},{"issue":"15","key":"e_1_3_4_28_1","first-page":"2549","article-title":"Preliminary results from a phase 1\/2 study of BDC-1001, a novel HER2 targeting TLR7\/8 immune-stimulating antibody conjugate (ISAC), in patients (pts) with advanced HER2-expressing solid tumors","volume":"39","author":"Crd SM","year":"2021","unstructured":"Crd SM, Hanna GJ, Li BT, Moore KN, Pegram MD, Rasco DW, Spira AI, Alonso M, Fang L, Husain A, et al. Preliminary results from a phase 1\/2 study of BDC-1001, a novel HER2 targeting TLR7\/8 immune-stimulating antibody conjugate (ISAC), in patients (pts) with advanced HER2-expressing solid tumors. J Clin Oncol. 2021;39(15):2549.","journal-title":"J Clin Oncol"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2012.38"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.847835"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.3110"},{"key":"e_1_3_4_32_1","first-page":"317","article-title":"A phase 1\/1b study of SBT6050, a HER2-directed monoclonal antibody conjugated to a toll-like receptor 8 agonist, in subjects with advanced HER2-expressing solid tumors","volume":"8","author":"Emens L","year":"2020","unstructured":"Emens L, Beeram, M, Hamilton E, Piha-Paul S, Odegard V, Hamke S, Hunder N, Klempner S. A phase 1\/1b study of SBT6050, a HER2-directed monoclonal antibody conjugated to a toll-like receptor 8 agonist, in subjects with advanced HER2-expressing solid tumors. J ImmunoTherapy Cancer. 2020;8:317.","journal-title":"J ImmunoTherapy Cancer"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.08.491"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-00947-7"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2021-1858"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0738-2"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S247050"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201142064"},{"key":"e_1_3_4_39_1","first-page":"1165","article-title":"Impact of SD-101, a toll-like receptor 9 class C (TLR9C), agonist on myeloid derived suppressor cells","volume":"10","author":"Ghosh C","year":"2022","unstructured":"Ghosh C. Impact of SD-101, a toll-like receptor 9 class C (TLR9C), agonist on myeloid derived suppressor cells. J ImmunoTherapy Cancer. 2022;10: 1165.","journal-title":"J ImmunoTherapy Cancer"},{"key":"e_1_3_4_40_1","unstructured":"Idera pharmaceuticals announces results from illuminate-301 trial of tilsotolimod + ipilimumab in anti-pd-1 refractory advanced melanoma."},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.1564"},{"key":"e_1_3_4_42_1","unstructured":"Tallac Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for TAC-001 a First-in-Class Toll-like Receptor 9 (TLR9) Agonist Antibody Conjugate for Patients with Advanced Solid Tumors."},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2021-1721"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04232-5"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002426"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002408"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0465"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1859064"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1760061"},{"issue":"11","key":"e_1_3_4_50_1","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002953","article-title":"Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy","volume":"9","author":"Alvarez M","year":"2021","unstructured":"Alvarez M, Molina C, De Andrea CE, Fernandez-Sendin M, Villalba M, Gonzalez-Gomariz J, Ochoa C, Teijeira A, Glez-Vaz J, Aranda F, Sanmamed MF, Rodriguez-Ruiz ME, Fan X, Shen WH, Berraondo P, Quintero M, Melero I, et al. Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy. J Immunother Cancer. 2021;9(11).","journal-title":"J Immunother Cancer"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005011"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000266"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.93397"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1608555113"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1411"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0743"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0280"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12160-2"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1922-8"},{"key":"e_1_3_4_60_1","first-page":"756","article-title":"INCLINE-101, a phase 1\/2, open label, dose escalation and expansion study of TAC-001 (a TLR9 agonist conjugated to a CD22 antibody) in patients with select advanced or metastatic solid tumors","volume":"10","author":"Perez C","year":"2022","unstructured":"Perez C, Henry J, Humphries T, Kim S, Diab A, Harrabi O, Jin F, Wan H, Bermingham C, El-Kouiery A, et al. INCLINE-101, a phase 1\/2, open label, dose escalation and expansion study of TAC-001 (a TLR9 agonist conjugated to a CD22 antibody) in patients with select advanced or metastatic solid tumors. J ImmunoTherapy Cancer. 2022;10:756.","journal-title":"J ImmunoTherapy Cancer"},{"issue":"2","key":"e_1_3_4_61_1","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000940","article-title":"In situ immunization of a TLR9 agonist virus-like particle enhances anti-PD1 therapy","volume":"8","author":"Cheng Y","year":"2020","unstructured":"Cheng Y, Lemke-Miltner CD, Wongpattaraworakul W, Wang Z, Chan CHF, Salem AK, Weiner GJ, Simons AL, et al. In situ immunization of a TLR9 agonist virus-like particle enhances anti-PD1 therapy. J Immunother Cancer. 2020;8(2).","journal-title":"J Immunother Cancer"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1900742"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0568-2"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1442169"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2021.188526"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00507-y"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1115641"},{"key":"e_1_3_4_68_1","first-page":"10","article-title":"Local anesthetics elicit immune-dependent anticancer effects","volume":"2022","author":"Bezu L","year":"2022","unstructured":"Bezu L, Wu Chuang A, Sauvat A, Humeau J, Xie W, Cerrato G, Liu P, Zhao L, Zhang S, Le Naour J, Pol J, van Endert P, Kepp O, Barlesi F, Kroemer G, et al. Local anesthetics elicit immune-dependent anticancer effects. J Immunother Cancer. 2022;2022:10.","journal-title":"J Immunother Cancer"}],"container-title":["OncoImmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/2162402X.2023.2180237","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T16:40:54Z","timestamp":1780418454000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/2162402X.2023.2180237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,17]]},"references-count":67,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,12,31]]}},"alternative-id":["10.1080\/2162402X.2023.2180237"],"URL":"https:\/\/doi.org\/10.1080\/2162402x.2023.2180237","relation":{},"ISSN":["2162-402X"],"issn-type":[{"value":"2162-402X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,17]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=koni20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=koni20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-01-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-09","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2180237"}}